The results showed that patients in the rosuvastatin group experienced a significant reduction in galectin-3 levels after 4 weeks of treatment, whereas no significant change was observed in the atorvastatin group (37), suggesting that rosuvastatin may have a stronger effect in modulating biomarkers related to myocardial fibrosis. The gene discussed is LGALS3; the disease is Myocardial fibrosis.